The estimated Net Worth of Timothy J. Sangiovanni is at least $105 millier dollars as of 13 March 2020. Mr. Sangiovanni owns over 4,000 units of Zevra Therapeutics Inc stock worth over $104,580 and over the last 7 years he sold KMPH stock worth over $0. In addition, he makes $0 as Vice President et Corporate Controller at Zevra Therapeutics Inc.
Timothy has made over 4 trades of the Zevra Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of KMPH stock worth $800 on 13 March 2020.
The largest trade he's ever made was buying 8,000 units of Zevra Therapeutics Inc stock on 9 March 2020 worth over $2,000. On average, Timothy trades about 1,636 units every 47 days since 2018. As of 13 March 2020 he still owns at least 18,000 units of Zevra Therapeutics Inc stock.
You can see the complete history of Mr. Sangiovanni stock trades at the bottom of the page.
Timothy J. Sangiovanni serves as Vice President, Corporate Controller of the Company. Mr. Sangiovanni has served as our vice president, corporate controller since February 2017. Previously, Mr. Sangiovanni served as our director of financial reporting since August 2015. Prior to joining our company, Mr. Sangiovanni served as manager of internal audit – worldwide, with Tupperware Brands Corporation, a publicly-held marketer of home and personal care products from April 2013 to August 2015. From January 2007 to March 2013, Mr. Sangiovanni served in a variety of roles with KPMG, LLP, including audit associate, senior audit associate and audit manager. Mr. Sangiovanni was a billing analyst with Switch and Data Facilities, Inc. (n/k/a Equinix, Inc.) from October 2005 to December 2006. Mr. Sangiovanni received his B.A. in Accounting from the University of South Florida and is a certified public accountant in the state of Florida.
Timothy Sangiovanni is 36, he's been the Vice President et Corporate Controller of Zevra Therapeutics Inc since 2017. There are 14 older and no younger executives at Zevra Therapeutics Inc. The oldest executive at Zevra Therapeutics Inc is Richard W. Pascoe, 57, who is the Exec. Chairman.
Timothy's mailing address filed with the SEC is C/O KEMPHARM, INC., 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION, FL, 34747.
Over the last 10 years, insiders at Zevra Therapeutics Inc have traded over $0 worth of Zevra Therapeutics Inc stock and bought 3,083,371 units worth $9,282,809 . The most active insiders traders include Street Capital Master Fund,..., David S Tierney et Travis C Mickle. On average, Zevra Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $246,727. The most recent stock trade was executed by R. La Duane Clifton on 13 January 2023, trading 635 units of KMPH stock currently worth $3,689.
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
Zevra Therapeutics Inc executives and other stock owners filed with the SEC include: